Key Points
- EVP Francisco Fraga sold 600 McKesson shares for $630,000 under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. He retained 5,064 shares.
- McKesson reported quarterly EPS of $11.68, beating the $10.72 consensus, and revenue of $110.96 billion, up 7.5% year over year and above expectations.
- Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes, operating improvements and GLP-1 momentum.
McKesson Corporation (NYSE:MCK - Get Free Report) EVP Francisco Fraga sold 600 shares of the firm's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $1,050.00, for a total transaction of $630,000.00. Following the sale, the executive vice president owned 5,064 shares of the company's stock, valued at approximately $5,317,200. This represents a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Francisco Fraga also recently made the following trade(s):
- On Thursday, October 15th, Francisco Fraga sold 800 shares of McKesson stock. The stock was sold at an average price of $995.80, for a total transaction of $796,640.00.
McKesson Stock Performance
Shares of McKesson stock opened at $1,075.38 on Friday. The company has a 50-day simple moving average of $934.72 and a two-hundred day simple moving average of $866.92. The stock has a market capitalization of $125.38 billion, a PE ratio of 27.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.27. McKesson Corporation has a 52-week low of $723.68 and a 52-week high of $1,121.50.
McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating analysts' consensus estimates of $10.72 by $0.96. McKesson had a net margin of 1.12% and a negative return on equity of 235.48%. The firm had revenue of $110.96 billion for the quarter, compared to analysts' expectations of $109.90 billion. During the same quarter in the prior year, the company posted $9.86 earnings per share. The business's revenue for the quarter was up 7.5% on a year-over-year basis. As a group, equities research analysts forecast that McKesson Corporation will post 44.71 EPS for the current fiscal year.
McKesson Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 annualized dividend and a yield of 0.3%. McKesson's dividend payout ratio is 9.67%.
McKesson News Roundup
Here are the key news stories impacting McKesson this week:
- Positive Sentiment: For fiscal Q2 2027, McKesson reported adjusted EPS of $11.68 versus analyst estimates near $10.70, while revenue of about $111 billion also topped expectations and grew roughly 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
- Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes, operating improvements and GLP-1 momentum. The company also completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services footprint. Earnings Call Highlights: Raised Guidance, GLP-1 Momentum
- Positive Sentiment: Several firms raised targets, including TD Cowen, Leerink Partners and Evercore ISI to $1,200; Deutsche Bank raised its target to $1,120. RBC also praised McKesson’s execution, and a Seeking Alpha analysis described normalized earnings as supporting an attractive valuation. TD Cowen Raises Price Target
- Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged trading plan to cover tax withholding on vested equity awards; he retained 5,064 shares, making the transaction less indicative of a change in business outlook. SEC Filing
- Negative Sentiment: RBC’s “sector perform” rating came with a $965 target—below the recent share price—suggesting limited upside in that firm’s view despite its target increase. RBC on McKesson’s Execution
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Nvwm LLC raised its stake in McKesson by 933.3% during the 3rd quarter. Nvwm LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 28 shares during the last quarter. Delos Wealth Advisors LLC purchased a new position in shares of McKesson in the 2nd quarter worth $27,000. Trellis Wealth Advisors LLC purchased a new position in shares of McKesson in the 3rd quarter worth $32,000. GK Wealth Management LLC purchased a new position in shares of McKesson in the 3rd quarter worth $38,000. Finally, Curry Webb Wealth Management LLC bought a new stake in shares of McKesson in the third quarter worth $38,000. 85.07% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
MCK has been the topic of several recent analyst reports. TD Cowen increased their target price on McKesson from $1,006.00 to $1,200.00 and gave the company a "buy" rating in a research note on Thursday. UBS Group boosted their price target on McKesson from $1,080.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Friday, October 16th. Leerink Partners upped their price target on McKesson from $1,070.00 to $1,200.00 and gave the company an "outperform" rating in a report on Thursday. Robert W. Baird set a $1,015.00 price target on McKesson in a report on Thursday, August 6th. Finally, Evercore reaffirmed an "outperform" rating and set a $950.00 price objective (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $1,023.24.
Get Our Latest Stock Analysis on MCK
About McKesson
(
Get Free Report)
McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.
McKesson's principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
